Analysis and Commentary STEVEN GROSSMAN 2/19/21 Analysis and Commentary STEVEN GROSSMAN 2/19/21 "FDA Exceptionalism," Redux (Again) Read More Analysis and Commentary STEVEN GROSSMAN 2/13/21 Analysis and Commentary STEVEN GROSSMAN 2/13/21 FDA-related Provision of House Reconciliation Bill Read More Advocacy at a Glance STEVEN GROSSMAN 2/13/21 Advocacy at a Glance STEVEN GROSSMAN 2/13/21 Under the House reconciliation bill, FDA would gain $500 million in no-year money to support its COVID-19 activities. The Alliance issued a statement of support for these funds. Read More Analysis and Commentary STEVEN GROSSMAN 2/5/21 Analysis and Commentary STEVEN GROSSMAN 2/5/21 Alliance's "Ask" for FY 22: Member Input Is Requested Read More Advocacy at a Glance STEVEN GROSSMAN 2/5/21 Advocacy at a Glance STEVEN GROSSMAN 2/5/21 The Senate has announced committee assignments. Senator Merkley will chair the Ag/FDA Appropriations Subcommittee and Senator Hoeven will be the Ranking Member. Read More Analysis and Commentary STEVEN GROSSMAN 1/29/21 Analysis and Commentary STEVEN GROSSMAN 1/29/21 Biden's Budget Request for FY 22 and Related Issues Read More Advocacy at a Glance STEVEN GROSSMAN 1/29/21 Advocacy at a Glance STEVEN GROSSMAN 1/29/21 Representatives Bishop and Fortenberry have been formally named as Chair and Ranking Member, respectively, on the House Appropriations Subcommittee on Ag/FDA. Read More Analysis and Commentary STEVEN GROSSMAN 1/21/21 Analysis and Commentary STEVEN GROSSMAN 1/21/21 Leadership and FDA Appropriation for FY 22 Read More Advocacy at a Glance STEVEN GROSSMAN 1/22/21 Advocacy at a Glance STEVEN GROSSMAN 1/22/21 Dr. Woodcock is the new Acting Commissioner. Alliance members and other FDA stakeholders are encouraged to express thanks to Congress for supporting FDA. Read More Analysis and Commentary STEVEN GROSSMAN 1/16/21 Analysis and Commentary STEVEN GROSSMAN 1/16/21 Supporting a Budget Increase for FDA for FY 22 Read More Advocacy at a Glance STEVEN GROSSMAN 1/16/21 Advocacy at a Glance STEVEN GROSSMAN 1/16/21 Congressional organizing, impeachment, inauguration, and COVID-19 planning are all part of changes in DC. Read More Analysis and Commentary STEVEN GROSSMAN 1/8/21 Analysis and Commentary STEVEN GROSSMAN 1/8/21 Now We Know Who'll Be in Charge Read More Advocacy at a Glance STEVEN GROSSMAN 1/8/21 Advocacy at a Glance STEVEN GROSSMAN 1/8/21 FDA’s share of the appropriations and stimulus bill are described, with a link for more detail. Read More STEVEN GROSSMAN 12/21/20 STEVEN GROSSMAN 12/21/20 FY 21 Appropriations Provisions and COVID-19 Relief / Stimulus Provisions Related to FDA Read More Advocacy at a Glance STEVEN GROSSMAN 12/18/20 Advocacy at a Glance STEVEN GROSSMAN 12/18/20 What Will Actually Get Funded at FDA in FY 21? Read More Advocacy at a Glance STEVEN GROSSMAN 12/18/20 Advocacy at a Glance STEVEN GROSSMAN 12/18/20 House-Senate Near Completion of Combo Appropriations/COVID-19 Relief Bill Read More Analysis and Commentary STEVEN GROSSMAN 12/10/20 Analysis and Commentary STEVEN GROSSMAN 12/10/20 COVID-19 Vaccine Update: A Briefing from the FDA Read More Advocacy at a Glance STEVEN GROSSMAN 12/11/20 Advocacy at a Glance STEVEN GROSSMAN 12/11/20 FDA Commissioner and CBER Director Provide Insights on Vaccines at Alliance Briefing Read More Analysis and Commentary STEVEN GROSSMAN 12/5/20 Analysis and Commentary STEVEN GROSSMAN 12/5/20 CDRH Update and Future Priorities Read More Advocacy at a Glance STEVEN GROSSMAN 12/5/20 Advocacy at a Glance STEVEN GROSSMAN 12/5/20 CDRH Director Presents at Alliance Webinar Read More Newer Posts Older Posts
Analysis and Commentary STEVEN GROSSMAN 2/19/21 Analysis and Commentary STEVEN GROSSMAN 2/19/21 "FDA Exceptionalism," Redux (Again) Read More
Analysis and Commentary STEVEN GROSSMAN 2/13/21 Analysis and Commentary STEVEN GROSSMAN 2/13/21 FDA-related Provision of House Reconciliation Bill Read More
Advocacy at a Glance STEVEN GROSSMAN 2/13/21 Advocacy at a Glance STEVEN GROSSMAN 2/13/21 Under the House reconciliation bill, FDA would gain $500 million in no-year money to support its COVID-19 activities. The Alliance issued a statement of support for these funds. Read More
Analysis and Commentary STEVEN GROSSMAN 2/5/21 Analysis and Commentary STEVEN GROSSMAN 2/5/21 Alliance's "Ask" for FY 22: Member Input Is Requested Read More
Advocacy at a Glance STEVEN GROSSMAN 2/5/21 Advocacy at a Glance STEVEN GROSSMAN 2/5/21 The Senate has announced committee assignments. Senator Merkley will chair the Ag/FDA Appropriations Subcommittee and Senator Hoeven will be the Ranking Member. Read More
Analysis and Commentary STEVEN GROSSMAN 1/29/21 Analysis and Commentary STEVEN GROSSMAN 1/29/21 Biden's Budget Request for FY 22 and Related Issues Read More
Advocacy at a Glance STEVEN GROSSMAN 1/29/21 Advocacy at a Glance STEVEN GROSSMAN 1/29/21 Representatives Bishop and Fortenberry have been formally named as Chair and Ranking Member, respectively, on the House Appropriations Subcommittee on Ag/FDA. Read More
Analysis and Commentary STEVEN GROSSMAN 1/21/21 Analysis and Commentary STEVEN GROSSMAN 1/21/21 Leadership and FDA Appropriation for FY 22 Read More
Advocacy at a Glance STEVEN GROSSMAN 1/22/21 Advocacy at a Glance STEVEN GROSSMAN 1/22/21 Dr. Woodcock is the new Acting Commissioner. Alliance members and other FDA stakeholders are encouraged to express thanks to Congress for supporting FDA. Read More
Analysis and Commentary STEVEN GROSSMAN 1/16/21 Analysis and Commentary STEVEN GROSSMAN 1/16/21 Supporting a Budget Increase for FDA for FY 22 Read More
Advocacy at a Glance STEVEN GROSSMAN 1/16/21 Advocacy at a Glance STEVEN GROSSMAN 1/16/21 Congressional organizing, impeachment, inauguration, and COVID-19 planning are all part of changes in DC. Read More
Analysis and Commentary STEVEN GROSSMAN 1/8/21 Analysis and Commentary STEVEN GROSSMAN 1/8/21 Now We Know Who'll Be in Charge Read More
Advocacy at a Glance STEVEN GROSSMAN 1/8/21 Advocacy at a Glance STEVEN GROSSMAN 1/8/21 FDA’s share of the appropriations and stimulus bill are described, with a link for more detail. Read More
STEVEN GROSSMAN 12/21/20 STEVEN GROSSMAN 12/21/20 FY 21 Appropriations Provisions and COVID-19 Relief / Stimulus Provisions Related to FDA Read More
Advocacy at a Glance STEVEN GROSSMAN 12/18/20 Advocacy at a Glance STEVEN GROSSMAN 12/18/20 What Will Actually Get Funded at FDA in FY 21? Read More
Advocacy at a Glance STEVEN GROSSMAN 12/18/20 Advocacy at a Glance STEVEN GROSSMAN 12/18/20 House-Senate Near Completion of Combo Appropriations/COVID-19 Relief Bill Read More
Analysis and Commentary STEVEN GROSSMAN 12/10/20 Analysis and Commentary STEVEN GROSSMAN 12/10/20 COVID-19 Vaccine Update: A Briefing from the FDA Read More
Advocacy at a Glance STEVEN GROSSMAN 12/11/20 Advocacy at a Glance STEVEN GROSSMAN 12/11/20 FDA Commissioner and CBER Director Provide Insights on Vaccines at Alliance Briefing Read More
Analysis and Commentary STEVEN GROSSMAN 12/5/20 Analysis and Commentary STEVEN GROSSMAN 12/5/20 CDRH Update and Future Priorities Read More
Advocacy at a Glance STEVEN GROSSMAN 12/5/20 Advocacy at a Glance STEVEN GROSSMAN 12/5/20 CDRH Director Presents at Alliance Webinar Read More
